Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation and Phase 2 Study of Alisertib (MLN8237) in Adult Patients With Solid Tumors
2008-006981-27Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alisertib in Nonhematologic neoplasms, small cell lung cancer (SCLC), bronchial carcinoma and 3 more (2 arms), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Phase 1 safety and tolerability. Started Nov 2010; status: completed.
02
Drugs
alisertib
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)bronchial carcinomabreast cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on 2008-006981-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006981-27.